Search by Ticker
Gilead Sciences (NASDAQ:GILD)
The following stock analysis is based on 10.1 years of data (i.e. since Feb 08, 2013). All the stock history has been downloaded.
Gilead Sciences trades on the NasdaqGS exchange in USD dollars.
It is in the sector.
It is currently trading at $81.45 ($81.29 the previous day).It pays a 3.59% dividend.
The next reporting date is in 34 days (2023 05 04).
CNN estimates profits for the upcoming quarter will be $1.55 per share ($6.3B). The current Canada / US exchange rate is 1.35534.
Over the past 12 months, $0 worth of shares have been purchased and $3393250 worth of shares have been sold by insiders.
The year over year average increase is 1.2% per year assuming steady exponential growth. The actual 5 year average is -0.56. Details on the individual increase in one year intervals is provided below.
|Past Performance||Average Price||Percent Change|
|1 year||71.93188||6.4||+ Above Average|
|2 year||67.584097014925||-0.1||+ Above Average|
|3 year||67.664004225352||2.4||+ Above Average|
|4 year||66.095621088435||-6.2||- Below Average|
|5 year||70.490076045627||-5.3||- Below Average|
The worst drop it has had in recent years is -53.0%. It has a shape to the stock curve, which means
Is It Time to Buy These Ultra-Cheap Dividend Stocks?Wed, 29 Mar 2023 20:00:00 High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor. The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.... Read Full Article
Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. CommunitiesWed, 29 Mar 2023 14:35:00 Gilead Sciences, Inc. (Nasdaq:GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based ...... Read Full Article
Investors more bullish on Gilead Sciences (NASDAQ:GILD) this week as stock climbs 4.1%, despite earnings trending downwards over past yearWed, 29 Mar 2023 12:00:38 The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...... Read Full Article
Gilead Sciences (GILD) Gains As Market Dips: What You Should KnowTue, 28 Mar 2023 21:50:09 Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.... Read Full Article
Gilead Sciences Could Retreat Further From HereMon, 27 Mar 2023 13:25:00 Biopharmaceutical company Gilead Sciences makes and distributes many drugs but today I am more interested in the position of the charts and indicators. Bottom-line strategy: GILD is a volatile stock that can move up or down quickly depending on the ...... Read Full Article
Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug ApprovalThu, 23 Mar 2023 17:51:05 Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.... Read Full Article
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should KnowWed, 22 Mar 2023 21:50:09 Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.... Read Full Article
Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 StudyWed, 22 Mar 2023 18:38:06 Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.... Read Full Article
Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They AreWed, 22 Mar 2023 13:30:00 NORTHAMPTON, MA / ACCESSWIRE / March 22, 2023 / Gilead Sciences Every Friday for more than two years, a community church in North Wales, U.K., would transform into a one-stop shop of social services for people experiencing homelessness. Everything ...... Read Full Article
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma PatientsTue, 21 Mar 2023 17:19:40 Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of ...... Read Full Article
Nurix's (NRIX) Stock Up Due to License Option Exercise by GileadTue, 21 Mar 2023 14:05:02 Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.... Read Full Article
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell LymphomaTue, 21 Mar 2023 13:37:00 SANTA MONICA, Calif., March 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was ...... Read Full Article
Gilead Exercises First License Option Under Agreement With Nurix TherapeuticsMon, 20 Mar 2023 16:17:29 Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is ...... Read Full Article
Nurix’s stock rallies on Gilead’s optionMon, 20 Mar 2023 13:00:00 MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix’s targeted protein degrader molecule, which is being considered as a ...... Read Full Article
Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479Mon, 20 Mar 2023 12:30:00 FOSTER CITY, Calif. and SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s ...... Read Full Article
Gilead Sciences (GILD) Gains But Lags Market: What You Should KnowThu, 16 Mar 2023 21:45:09 Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.... Read Full Article
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?Thu, 16 Mar 2023 16:10:04 Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.... Read Full Article
Here’s Why Gilead Sciences (GILD) Outperformed in Q4Thu, 16 Mar 2023 11:30:50 Ariel Investments, an investment management company, released its “Ariel Global Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return ...... Read Full Article
Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite SensiblyThu, 16 Mar 2023 11:00:50 Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...... Read Full Article
Gilead Sciences (GILD) Stock Moves -0.15%: What You Should KnowWed, 15 Mar 2023 21:50:09 In the latest trading session, Gilead Sciences (GILD) closed at $79.65, marking a -0.15% move from the previous day.... Read Full Article